Dr. Hu replaces Jay Galeota, who recently stepped down from the board.
Dr. Hu is an experienced advisor, having worked with Mass General Brigham Ventures and Clarion prior to joining Morningside Technology Advisory.
She received her Ph.D. in Biological Sciences in Public Health from Harvard University.
Apnimed's AD109 has the potential to be the first oral pharmacologic that treats OSA airway closures at night.
It is a first-in-class, novel, investigational combination dosed once daily at bedtime and is designed to treat OSA patients across a broad spectrum of disease severity.
AD109 combines a selective norepinephrine reuptake inhibitor (atomoxetine) with Apnimed's new chemical entity and selective antimuscarinic (aroxybutynin).
AD109 targets key neurological pathways in OSA that cause upper airway closure during sleep by activating the upper airway dilator muscles and maintaining an open airway during sleep.
This drug combination has the potential to become a safe, effective, and convenient treatment for OSA, addressing some of the key limitations of the current device and surgical approaches that are the standard of care treatments.
AD109 is currently completing Phase 2 clinical trials, after which Apnimed plans to meet with FDA to discuss the Phase 3 development program.
Apnimed is a clinical-stage pharmaceutical company working to transform the treatment of sleep apnea based on a simple idea patients with obstructive sleep apnea could benefit from treatment with a safe and effective oral medication dosed once daily at bedtime.
Apnimed's lead development program targets the neurologic control of upper airway muscles to maintain an open airway during sleep.
Based in Cambridge, Mass., the company is developing a portfolio of novel pharmacologic therapies for sleep apnea and related disorders.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial